Assessing the acceptability and usability of MedSafer, a patient-centered electronic deprescribing tool

评估以患者为中心的电子停药工具 MedSafer 的可接受性和可用性

阅读:1

Abstract

BACKGROUND: Deprescribing is the clinically supervised process of stopping or reducing medications that are no longer beneficial. MedSafer is an electronic decision support tool that guides healthcare providers (HCPs) through the deprescribing process. We recently developed a novel patient-facing version of the software, allowing patients and caregivers to generate a personalized deprescribing report to bring to their prescriber. OBJECTIVE: The study aimed to evaluate the usability and acceptability of MedSafer among older adults, caregivers, and community HCPs (physicians, nurse practitioners and pharmacists). METHOD: A mixed-methods feasibility study was conducted with a convenience sample of 100 older adults/caregivers, and 25 healthcare practitioners. Participants were invited to test MedSafer and answer telephone or electronic surveys via RedCap. The Extended Technology Acceptance Model (TAM2) and System Usability Scale (SUS) were used for evaluation. A semi-structured interview was also conducted with a subset of participants (5 per group) who were selected on a volunteer basis, and thematic analysis was used following Braun & Clarke's approach. RESULTS: Healthcare providers scored more favorably on TAM2 constructs such as perceived usefulness (PU) (median: 4.25 for HCPs; 3.75 for caregivers; 3.00 for patients), and SUS compared to patients and caregivers (mean: 79.50 for HCPs; 52.95 for caregivers; 55.75 for patients). Thematic analysis revealed that participants recognized MedSafer as an empowering tool but noted the need for some usability improvements. CONCLUSION: MedSafer is a promising tool to support deprescribing conversations. Enhancing usability, accessibility, and patient education may improve adoption.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。